CARES试验事后分析:痛风患者降尿酸治疗期间慢性肾脏病进展延缓
该研究为CARES试验事后分析,纳入接受非布司他或别嘌醇降尿酸治疗超过6个月的痛风患者,计算eGFR斜率。在5002例患者中,3264例(65.3%)在降尿酸治疗期间eGFR升高;平均sUA水平升高与eGFR斜率下降显著相关,平均sUA低于6 mg/dL与eGFR下降风险降低显著相关。
要点
- 痛风患者降尿酸治疗期间,超过半数eGFR未下降。
- 平均sUA每升高1 mg/dL,eGFR斜率下降(校正β -0.1912)。
- 降尿酸治疗中平均sUA低于6 mg/dL与eGFR下降风险降低相关(校正OR 0.66)。
核心结论
- 痛风患者降尿酸治疗期间维持低sUA水平与CKD进展风险降低显著相关。
研究设计与样本
- CARES试验事后分析,纳入接受非布司他或别嘌醇降尿酸治疗超过6个月的痛风患者5002例,中位随访2.5年。
主要发现
- 3264例(65.3%)患者在降尿酸治疗期间eGFR升高。
- 平均sUA每升高1 mg/dL,eGFR斜率下降,校正β为-0.1912。
- 倾向评分匹配分析显示,降尿酸治疗期间平均sUA低于6 mg/dL与eGFR下降风险降低显著相关,校正OR 0.66(95%CI 0.57-0.77)。
关键数值与推荐
- 平均sUA低于6 mg/dL与eGFR下降风险降低相关(校正OR 0.66,95%CI 0.57-0.77)。
临床怎么用
- 痛风患者降尿酸治疗期间可考虑将sUA控制在6 mg/dL以下以延缓CKD进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Based on the hypothesis that hyperuricemia is a modifiable risk factor for chronic kidney disease (CKD) progression, there is an expectation that urate-lowering therapy (ULT) could delay the progression of CKD. Here, we investigated changes in kidney function and the association of the serum uric acid (sUA) level and kidney function during ULT in patients with gout. To do this we conducted post-hoc analysis on patients who received ULT with either febuxostat or allopurinol for more than six months in the CARES trial. The estimated glomerular filtration rate (eGFR) slope (annual rate of change in eGFR) was calculated using the CKD-EPI creatinine equation and linear mixed modeling. Among the 5,002 patients with gout, 3,264 (65.3%) demonstrated an increased eGFR while receiving ULT over a median follow-up of 2.5 years. Increased average sUA levels were significantly associated with declines in eGFR slope (per 1 mg/dL increase, (adjusted beta of -0.1912). Propensity score matched analysis demonstrated a significant association between low average sUA levels below 6 mg/dL during ULT and a reduced risk of eGFR decline (adjusted odds ratio: 0.66, 95% confidence interval 0.57-0.77). Despite the well-documented natural decline of eGFR over time in the general population, more than half of the patients enrolled in the CARES trial did not experience declines in eGFR while receiving ULT. Thus, our study shows maintaining low sUA levels with ULT was significantly associated with a decreased risk of CKD progression in patients with gout.
引用
- Ghang B, Park J, Lee JS, et al. Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. 2024. PMID: 39551133. doi:10.1016/j.kint.2024.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。